A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria

Summary

A double blind, randomized, cross over study in type 1 diabetic patients. 20 patients, age 18-65 years is treated with spironolacton (Hexalacton (R)) for 60 days followed by 60 days treatment with placebo(or opposite). Primary aim: albuminuria, an expected decrease during hexalacton treatment. Secondary aim: ambulatory blood pressure, GFR, plasma-renin, angiotensin, aldosteron.

Timeline

Start

2009-03

Primary completion

2010-03

Completion

2010-03

Drugs

Indications